Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zaloglanstat Phase 1 Study in Healthy Volunteers
NCT02179645Phase 1Completed
- Sponsor
- Glenmark Pharmaceuticals
- Start
- May 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zaloglanstat in osteoarthritis (OA), rheumatoid arthritis (RA) and pain (3 arms), sponsored by Glenmark Pharmaceuticals. Primary endpoint: Drug related adverse events (AEs) or any serious AEs at 15 days. Started May 2014; status: completed.
02
Drugs
zaloglanstat
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)pain
Beyond the preview
Go deeper on NCT02179645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02179645.